ArticleCancer immunology, immunotherapy : CII2014
Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines.
Article in Cancer immunology, immunotherapy : CII, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges.Clinical and experimental medicine · 2026Review
- Extracellular vesicles: biogenesis mechanism and impacts on tumor immune microenvironment.Journal of biomedical science · 2025Review
- The Extra-Tumoral Vaccine Effects of Apoptotic Bodies in the Advancement of Cancer Treatment.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- ApoBDs: a paradigm shift from cellular debris to therapeutic vehicles.Frontiers in endocrinology · 2025Review
- Apoptotic Vesicles: Therapeutic Mechanisms and Critical Issues.Journal of dental research · 2024Review
- Advances in biological functions and applications of apoptotic vesicles.Cell communication and signaling : CCS · 2023Review
- Apoptotic bodies: bioactive treasure left behind by the dying cells with robust diagnostic and therapeutic application potentials.Journal of nanobiotechnology · 2023Review
- Palmitoylated antigens for the induction of anti-tumor CD8Molecular therapy oncolytics · 2021Article
- Gold Compounds and the Anticancer Immune Response.Frontiers in pharmacology · 2021Review
- Review
- The Roles of Stroma-Derived Chemokine in Different Stages of Cancer Metastases.Frontiers in immunology · 2020Review
- Dendritic cells loaded with CD44Oncology letters · 2019Article
- Glycan-Modified Apoptotic Melanoma-Derived Extracellular Vesicles as Antigen Source for Anti-Tumor VaccinationCancers · 2019Article
- Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression.Molecular cancer · 2019Review
- Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes.Frontiers in immunology · 2018Article
- Tumor-Derived Apoptotic Vesicles: With Death They Do Part.Frontiers in immunology · 2018Review
- Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Targeted oncology · 2017Review
- Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.BMC immunology · 2017Article
- Dendritic cells that phagocytose apoptotic macrophages loaded with mycobacterial antigens activate CD8 T cells via cross-presentation.PloS one · 2017Article
- Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination.Small (Weinheim an der Bergstrasse, Germany) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since few leukemia-associated antigens (LAA) are characterized for acute myeloid leukemia (AML), apoptotic tumor cells constitute an attractive LAA source for DC-based vaccines, as they contain both characterized and unknown LAA. However, loading DC with apoptotic tumor cells may interfere with DC function. Previously, it was shown in mice that apoptotic blebs induce DC maturation, whereas apoptotic cell remnants (ACR) do not. Here, we analyzed human monocyte-derived DC (MoDC) functionality in vitro, after ingesting either allogeneic AML-derived ACR or blebs. We show that MoDC ingest blebs to a higher extent and are superior in migrating toward CCL19, as compared to ACR-loaded MoDC. Although MoDC cytokine production was unaffected, co-culturing bleb-loaded MoDC with T cells led to an increased T cell proliferation and IFNγ production. Moreover, antigen-specific CD8(+) T cells frequencies increased to 0.63 % by priming with bleb-loaded MoDC, compared to 0.16 % when primed with ACR-loaded MoDC. Importantly, CD8(+) T cells primed by bleb-loaded MoDC recognized their specific epitope at one to two orders of magnitude lower concentrations compared to ACR-loaded MoDC. In conclusion, superior ingestion efficiency and migration, combined with favorable T cell cytokine release and CD8(+) T cell priming ability and avidity, point to blebs as the preferred component of apoptotic leukemic cells for LAA loading of DC for the immunotherapy of AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.